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Abstract
Genetic engineering is an emerging technology that offers the potential to prevent, treat,
or cure genetic diseases. The technology can permanently alter the genome, providing an
alternative therapy to drugs and surgery. Specifically, gene therapy is a promising treatment
option for many incurable genetic diseases, such as cystic fibrosis and muscular cell dystrophy.
Our project gives rise to a better understanding ofTALENs and its uses in the genetic
engineering field.
TALENs, transcription activator-like effector nucleases, are a genetic engineering
teclmology that can be used for targeted gene modification. They are engineered proteins that
can bind to specific sequences of DNA and induce a double-stranded break. The DNA sequence
that the TALENs bind to is determined by the user; therefore the TALENs can be engineered to
target specific DNA sequences that cause genetic diseases. We used TALENs within the model
organism, nematode C. elegans, to explore their potential for use in gene therapy. By utilizing
TALENs to introduce a lin-31 mutant into the genome of C. elegans we aim to advance the
understanding ofTALENs as a genetic engineering tool and contribute to the research on the
docking site ofLIN-31 in the Ras/MAPK signaling pathway. Our group was successful in
creating the DNA that encodes for these TALENs proteins, providing a foundation for future
student researchers to continue on the project.
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Introduction and Significance
Background/Motivation
Genetic engineering is an emerging technology that offers the potential to permanently
alter the genome of organisms. Gene therapy uses genetic engineering technologies to treat many
incurable genetic diseases, such as cystic fibrosis and muscular cell dystrophy. It is an exciting
tield because the technology can petmanently alter the genome, providing an alternative therapy
to drugs and surgery.
There are many ways by which genetic engineering can be achieved. One of the most
common techniques is to use a nuclease to induce a double-stranded break in the genome. New
genetic information can be insetted at this break site (an insertion mutation) or genetic
infmmation can be deleted from the break site (a deletion mutation). After the genome is
mutated, it is repaired either by non-homologous end joining (NHEJ) or by homologous
recombination (HR). Non-homologous end joining allows the DNA to crash back together, while
homologous recombination requires the use of template DNA (which contains the same sequence
as the break site) to repair the broken ends. The variety in genetic engineering technology arises
from the different types of mutations they induce after the double-stranded break in the genome
and how this mutation is repaired.
TALENs, transcription activator-like effector nucleases, are a genetic engineering
technology that can be used for targeted gene modification. They are engineered proteins which
can bind to specific sequences of DNA and induce a double-stranded break. This break is then
repaired by either NHEJ or HR using template DNA. The user determines the DNA sequence
that the TALENs binds to; therefore the TALENs can be engineered to target specific DNA

sequences that cause genetic diseases, and therein lies its great potential as a therapeutic tool
(Cermak). For our senior design project we used TALENs within the model organism, nematode

C. elegans, to explore their potential for use in gene therapy. As a result of our research, we
concluded that TALENS enables much more precise targeting of DNA sequences, and is
therefore wotihy of continued testing and development. At the end of our report we will indicate
the next steps that might be taken with this promising technology.

Critique of Competing Technologies
The established methods for gene therapy include retroviruses, zinc finger nucleases, and
CRISPR. However, each ofthese technologies has significant drawbacks. As seen in Table 1,
TALENs offers an exciting approach to gene therapy because it addresses the issues seen with
the established methods for gene therapy.

Table 1. A comparison ofTALENs to the current approaches to gene therapy

Technology

•

•

Retroviruses

Zinc Finger
Nucleases
(ZFNs)

What it Does

•

The virus can insert
its DNA into the
host's genome

•

The vitus's DNA
permanently
becomes patt of the
host's genome and
is expressed using
the host's DNA
transcription and
translation
machinery

•

•

Engineered
proteins that can
target DNA
sequences and
induce a double
stranded break
This break is then
repaired by
injecting DNA that
acts as a template
forHR

Drawbacks

How TALEN s Addresses
these problems

•

Retroviruses
cutTently carmot be
engineered to
target specific
DNA sequences

•

TALENs can be
engineered to target
specific DNA
sequences

•

This can result in
undesired gene
modification: the
retrovirus could
insert at a location
in the genome that
turns on an
oncogene, causing
cancer

•

TALENs gives the
genetic engineer more
control over the gene
modification; they will
not randomly modify
the genome

•

Takes 5 days to
engineer

•

The creators of this
teclmology have
developed a kit which
provides a step by step
protocol to engineer the
TALENs

•

Data has been
published showing the
success ofTALENs

•

Takes 5 days to
engineer

•

Takes weeks or
months to engineer

•

Difficult to
engineer

•

Have a significant
failme rate

•

Takes weeks or
months to engineer

Technology

•

CRISPR

What it Does

•

•

Engineered
proteins composed
of a DNA binding
domain and a
nuclease

Drawbacks

•

Recently developed
technology

•

High rate of offtarget effects

Break is then
repaired by
injecting foreign
DNA

How TALEN s Addresses
these problems

•

TALENs is a more
established approach to
gene therapy and has
been studied in C.
elegans

•

Lower incidence of offtarget effects

A retrovirus is an RNA vitus that stores genetic information in the form of mRNA. The
mRNA is then conve1ied into DNA with the use of the enzyme reverse transcriptase and can then
be incorporated into the host cell's genome (Anson). Scientists have used retroviruses as vehicles
for delivering corrected gene segments (Anson). This has shown that retroviruses have high
efficiency when spreading their genetic information. However, a major problem with using
retrovituses to con·ect genetic mutations is that they cannot be engineered to target specific DNA
sequences and therefore could cause undesired gene modification. The retrovirus could insert
DNA in a location within the genome that tums on an oncogene, causing cancer. Because ofthis
drawback, new approaches to gene therapy were developed.
Zinc finger nucleases (ZFNs) attempt to address the problems seen with retroviruses.
ZFNs can be engineered to target specific sequences within the genome, as illustrated in Figure I
below:

Figure I: Structure of a Zinc Finger Nuclease ("What is").

As shown in Figure 1, after the ZFNs bind to the DNA, they are able to induce a doublestranded break. The genome is then modified either through homologous recombination with an
insetted plasmid or non-homologous end joining. ZFNs are composed of C2H2 zinc-finger
motifs, which are the DNA binding domain and a Fok l nuclease, an enzyme that can cut DNA.
Together these components create a targeted approach to genetic engineering and have been used
successfully to disrupt genes in the model organism C. elegans (Wood). However, ZFNs have
not become a widely used approach to genetic engineering because they are difficult to engineer
and expensive to create.
Recently developed approaches to gene therapy include CRISPR (Clustered Regularly
lnterspaced Sh011 Palindromic Repeats) and TALENs (Transcription Activator-Like Effector
N ucleases). Both of these technologies address the problems seen with retroviruses and ZFNs.
T ALENs and CRISPR are similar to the zinc finger nucleases; they are engineered proteins
composed of a DNA binding domain and a nuclease. The DNA binding domain in the CRISPR
system is guide RNA derived from bacteria and is fused to the endonuclease Cas9 (Chen). This
complex can then bind to and cut DNA. However, CRISPR is a recently developed technology

and preliminary research has shown that it has more off-target effects, or binding in undesired
locations. This is highlighted by a recently published study in which CRISPR was used to
modify the genome of non-viable human embryos. Eighty-six embryos were used in this
experiment, and only four contained the correct mutation (Cyranoski). Further data analysis
indicated that many of the embryos used in the study contained oli-target mutations, meaning
that CRISPR had modified the embryo's genome in an undesired location.
We have chosen to use the TALENs approach to genetic engineering because they can
be engineered to target specific DNA, have few limitations regarding the sequences they target,
are easy to engineer, and have less off-target effects than CRISPR.

Review ofTALENs Technology
TALENs are engineered proteins comprised of transcription activator-like (TAL)
effectors, the DNA binding domain of the protein, and a Fokl nuclease (Cermak). The TAL
effectors are DNA binding proteins produced by bacteria in the Xanthomonas genus (Cermak).
Because of this DNA binding capability, different TAL-effectors can be combined to create the
DNA binding domain of the TALENs protein. The binding domain is then fi.Jsed to a Fokl
nuclease, creating a protein that can target and induce a double stranded break at a specific
location. TALENs have been used to successfully alter the genomes of C. elegans, zebrafish,
tiuit flies, frogs, rats, and pigs (Joung). Most of these studies have used TALENs to induce
knockout mutations, or mutations facilitated by non-homologous end joining, in the organism's
genome (Joung). Specifically, our project will use TALENs to create a double stranded break,
which will then be repaired through homologous recombination with a repair plasmid. Such

homologous recombination is demonstrated in the image below through the process of "gene
correction" or "gene addition".
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Figure 2. Process of gene editing with a TALENs protein ("Custom").

As indicated in the graphic, the first step in using the TALENs technology is to identify
the DNA sequence that will be altered. This sequence is then put into the TALENs software, a
free online program developed by the creators ofTALENs. The user also inputs the location in
the genome where the T ALENs should cut. The program then generates the DNA sequence for
constructing TALENs that will target the desired location in the genome. Once the template has
been generated, the appropriate subunits from the TALENs plasmid kit are used to create the
TALENs DNA. This DNA is then transcribed into mRNA using an in vitro transcription kit.
After the mRNA is created, it is microinjected into the C. elegans, along with the repair plasmid.
The C. elegami' ribosomes then translate the TALENs mRNA into TALENs protein; this protein
can then target the desired DNA sequence. Targeting occurs because the TALENs DNA binding
domain contains only four types of repeating subunits, each corresponding to a specific
nucleotide. This allows the user to customize the order of these subunits, creating two TALENs

proteins that will bind to complementary strands of the desired DNA. Once the TALEN s proteins
bind, the Foki nuclease that is attached to the TALENs will induce a double stranded break in the
DNA.
In addition to making the TALENs DNA and mRNA, we will also construct a separate
plasmid containing the desired mutant sequence that will also be microinjected with the mRNA.
DNA repair machinery utilizes this plasmid as a template for homologous recombination. This
results in an altered gene at its endogenous site within the genome.

Statement of P1·oject Goal

Our project focuses on engineering TALENs to alter the gene /in-31, an important gene
in cell fate detennination in C. e/egans. Our goal is to create a modified version ofthe /in-31
gene, which is then translated into a mutated LIN-31 protein. We hypothesized that this mutation
will alter a putative Map Kinase docking site at the end of a Ras/Map Kinase signaling pathway.
The success of this project will be analyzed by screening the microinjected C. e/egans for
mutations. Both the constructed TALENs and the repair plasmid containing our altered sequence
will be microinjected into C. e/egans. If the TALENs were successful, the nematode's progeny
would contain the mutated version of our selected sequence. This mutation was hypothesized to
create a visible mutant phenotype in a specific sensitized genetic background.
Beyond scoring the phenotypes of the progeny of our TALENs C. e/egans, a cel-l assay
will also be used to analyze the project. Pools of worms will be lysed in order to extract their
DNA. This DNA will then be amplified using PCR or polymerase chain reaction. Cel-l, an
enzyme that cuts mismatched DNA, will be extracted from celery, and when incubated with the
PCR products from pools ofwmms, should reveal if the mutation is present. This DNA will also

be sequenced to determine if the TALENs were successful in mutating the C. elegans genome at
the desired location.

Back-up Plan
Due to the nature of scientific research, our design team ran into many issues that
required troubleshooting and redoing experiments. Therefore, we were unable to complete the
project in its entirety. However, we were able to create the TALENs DNA and have left a
detailed lab notebook for future students to use as a guide to fiJrther explore the potential of
TALENs as a genetic engineering tool. Our plan is to present our completed work and explore
possible explanations as to what went wrong.

Significance
Not only does this project give rise to a better understanding of cell fate determination in
C. elegans, but it also has the potential to increase our understanding of how transcription factors

work at the end of other Ras/Map Kinase signaling pathways. Mutations in these pathways are
found on approximately 70% of all human cancers (Sundaram). Therefore, successful
completion of our project will give rise to a better understanding of the details of the working of
this signaling pathway.
With our project we will be able to gain a deeper understanding of the genetic
engineering process. Because TALENs is a relatively new technology, our research has the
potential to advance the general understanding ofTALEN s and how they can be used in genetic
engineering, especially as a research tool. These advancements will bring TALENs-based
genetic therapy closer to the ultimate goal of using this technology to treat human genetic
diseases.
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1.0 Design and Construct
Ras/MAPK Signaling Pathway

One of the major goals of our project was to study a pathway known as the Ras/MAPK
signaling pathway. This pathway is conserved among many organisms including humans.
Ras/MAPK is involved in cell fate specification or the process by which cells determine their
specific cell type. This is because activation of the pathway causes a phosphorylation cascade
resulting in phosphorylated MAPK entering the nucleus and phosphorylating transcription
factors. Phosphorylation is a means of communication because it alters structural conformation
through the addition of a charged phosphate group. Transcription factors, or proteins that turn

genes on or off, play an important role in cell development, including cell fate specification,
depending on when they are activated or deactivated.
Specifically, we studied the effect of Ras/MAPK on the LIN-31 transcription factor. The
Miller lab has discovered a putative docking site on LIN-31 that tells MAP kinase where it
should bind and therefore indicates that LIN-31 should be phosphmylated. Because C. elegans
have been studied so extensively, we know they contain an anchor cell that utilizes the
Ras/MAPK signaling pathway to communicate with neighboring cells and affect their
development. If MAP kinase recognizes the docking site on LIN-31, it phosphorylates LIN-31
and the cells receive the proper signal to develop normally. However, we wanted to confirm that
the putative docking site is indeed a significant aspect of cell fate specification because of its role
in the Ras/MAPK signaling pathway. Therefore, if we can create a mutation in the lin-31 gene at
the location that codes for the docking site, we believe MAP kinase will be unable to recognize
where it should bind and therefore not properly phosphorylate LIN-31.

Within C. elegans, the anchor cell directs cells whether or not to become vulva cells. If
all of the processes occur properly, one vulva develops. If the docking site and therefore proper
phosphorylation of LIN-31 is dismpted, the cells do not receive the signal to develop into a vulva
at the transcriptional activation level, causing a vulvaless animal. This is a convenient phenotype
used to confirm our success because as hermaphrodites, vulvaless worms will internally fertilize
oocytes causing an easily visible "bag ofwmms."

1.1 Repair Plasmid
Introduction
In order to induce a specific mutation into the genome of C. elegans we first had to create
a repair plasmid with the desired mutation in it. This repair plasmid served as a template for
homologous recombination for the DNA strands and was incorporated into the genome of C.
elegans. In our project we aimed to mutate the putative docking site on the LIN-31 protein. The
potential docking site in the wild-type C. elegans contains arginine and lysine amino acids. Our
repair plasmid contains the DNA that codes for two alanine amino acids. By incorporating the
repair plasmid into the DNA we will disrupt this potential docking site and determine the effect
on cell fate development.

Arginine

Alanine

Lysine

Alanine

Figure 3. The original wild-type DNA and the DNA for the repair plasmid. The top strand of DNA shown is the
DNA from wild-type C. elegans with the DNA for the docking site in orange. The bottom strand is from the repair
plasmid DNA and contains the desired mutation. The DNA highlighted in purple is where our TALENs proteins
bind.

Details and Key Constraints
Dr. Leilani Miller, Associate Professor in Biology at Santa Clara University, and her lab
identified the site shown in Figure 3 as a potential docking site through analysis of consensus
sequences. This segment of DNA was identified to be a potential docking site through consensus
sequence analysis. This involves looking at DNA sequences of similar docking sites and
identifYing the similarities in the sequences. More specifically, other studies looked at conserved

sequences within MAP kinase targets until they determined sequences that act as docking sites
by knocking them out and performing kinase assays. The Miller Lab received the information on
what the docking site amino acid consensus sequences were, and then scanned lin-31 until that
site was found. The DNA (pLM 545) for /in-31 with these docking site mutations was already
created by Dr. Miller's lab. In order to create the desired repair plasmid we performed a TOPO
cloning reaction, which is seen in Figure 4.
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Figure 4. TOPO cloning reaction. The Topoisomerases create a break at their recognition site. The PCR product then
incorporates into the plasmid at this break (New).

TOPO cloning reactions use topoisomerases to uncoil and cut the plasmid DNA. This
allows the new DNA to insett itself into the plasmid before the plasmid rejoins. In order to do
this we amplified a short segment of DNA containing the mutations via a PCR reaction. By
amplifying the DNA, we ensured that it would be in high concentrations and have A overhangs,
making it ready to integrate when the topoisomerases cut the plasmid DNA.

Detailed Design Description
To amplify our DNA we used the PCR protocol from NEB entitled PCR Protocol for
Phusion'ID High-Fidelity DNA Polymerase (M0530). PCR reactions use the ability of DNA to
create a new strand from a complementary strand of DNA to create thousands of new copies of
the same DNA. In order to do this, primers (shmt, complimentary sequences at the start and end
of the desired fragment), a buffer, and nucleotides are added to the template DNA and put into a
thermocycler. While in the thermocycler, the contents are heated to denature the DNA and then
cooled and heated to promote replication in cycles, to amplify the DNA fragment.
The TOPO cloning reaction uses blue/white selection to make screening for inse1tion
easier. The Topoisomerases insert DNA within the LacZ gene on the plasmid. When the LacZ
gene is disrupted, then no B-galactosidase enzyme is produced. This allows for an easy screening
method because when grown on X -gal and IPTG plates the colonies with an intact LacZ and no
insert will be blue. The colonies in which the LacZ was disrupted and the PCR product was
inserted will be white.

Detailed Supporting Analysis
The TOPO cloning reaction is an established practice in the field of molecular biology
and has been cited in over 20,000 papers (TOPO).

Expected Results
As stated earlier it is easy to screen for the success of the TOPO cloning reaction because
it disrupts the LacZ gene. This process is called blue white selection. From this we expect to
have white colonies, which indicate that the DNA was integrated into the plasmid. After this
screening we willmn the DNA from the white colonies on gel electrophoresis, a technique used

to determine the size of DNA. We expect to see a single band at around 1500 base pairs. When
this is confhmed we will send the DNA out for sequencing to confirm that the mutation was
inserted into the plasmid.
Back-up Plan
We will still use TALENs and disrupt the docking site via non-homologous end-joining.
When the two ends of DNA crash back together in NHEJ, base pairs are lost and fhe gene is
disrupted.
Materials and Methods

For our reactions we followed two widely used protocols to determine the materials and
methods. We followed the PCR Protocol for Phusion® High-Fidelity DNA Polymerase (M0530)
protocol for the PCR reaction. We then used Invitrogen's guide for the TOPO® TA Cloning®
Kit for Sequencing.
Results
After performing the PCR and TOPO cloning reactions we observed approximately 50%
white colonies. The white color implied that the LacZ gene had been dismpted and the desired
DNA had been inserted into the repair plasmid. On the electrophoresis gel the DNA had a single
band at the expected size. This gel is shown in Figure 5. We then confirmed that we had the
correct DNA in the plasmid by sending the plasmid out for sequencing. The sequencing showed
that we had a plasmid with the conect mutation in it.

Figure 5: Electrophoresis Gel of repair plasmid. A single band around 1500bp was observed as expected.

Discussion
These results confirm that we created a repair plasmid containing the desired mutation we
hope to induce into the C. elegans. After the TALENs and repair plasmid have been
microinjected into the C. e/egans, it can be determined if the specific mutation was induced in
the C. elegans progeny by comparing the sequencing results to the mutant sequence in the repair
plasmid. This is an imp01tant step in the genetic engineering process, because it demonstrates
T ALEN s ability to do gene replacement.

1.2 TALENs DNA and mRNA
Introduction
TALEs are proteins discovered from the plant pathogen Xanthomomas. These TALE
proteins are able to recognize and bind to specific sequences of DNA (Joung).

Figure 6: TALE Binding protein ("TALEN").

Specifically, TALE proteins contain a DNA-binding stmcture made up of repeating loops
of 33-35 amino acids that allow the protein to bind to a specific DNA sequence. Each loop varies
with only two amino acids (Joung). This variety in amino acid loops determines which DNA
base pair the TALE will bind to. This is seen in Figure 7.

Figure 7: TALE binding loop bound to a specific DNA nucleotide (''TALENs for").

The users determine the order of the individual TALE loops (RVDs), and the order
determines where the TALEN s protein will bind. Each RVD is specific to a single base pair of
DNA. RVD NH binds to G, NI binds to A, HD binds to C, and NG binds to T (Joung).
Therefore, the order in which the RVDs are linked together detem1ines where the TALENs will

bind, allowing for targeted genome editing. It is necessary to design two TALENs proteins, one
that can bind to the top strand of DNA and one that can bind to the bottom strand of DNA. The
Foki nucleases of each of these TALENs then work together to create a double-stranded break in
the DNA sequence; this is seen in Figure 8.

LeftTALEN

Rioht TALEN

Figure 8: TALENs proteins (Sanjana).

Figure 8 shows the two domains that make up the TALENs proteins, the DNA binding
domain and the nuclease. This DNA binding domain of the TALENs protein is fused to a Foki
nuclease. The TALE part of the protein recognizes and binds to the DNA sequence ofthe user's
choosing, and the nuclease forms a dimer to create a double stranded break. Once this break is
created, the cell is prompted to repair itself by homologous recombination with the template
provided by the repair plasmid.
Details and Key Constraints

In order to create the double stranded break at the specific location, two TALENs
proteins must be made. One TALENs binds to the top strand of DNA and the other binds to the
bottom strand of DNA. The nucleases of these two proteins then dimerize and induce a donble
stranded break at the specific site. In order to create the two TALENs proteins, first the DNA

that encodes for these subunits must be put in the correct order. This is done in vitro. After the
TALENs DNA is made, it must be transcribed into mRNA. This mRNA, along with the repair
plasmid, can then be microinjected into the C. elegans. The ribosomes of the C. elegans will then
translate the TALENs mRNA, creating TALENs proteins in vivo. These proteins can then target
the specific DNA sequence and induce a double-stranded break, which can then be repaired by
the repair plasmid.
Detailed Design Description and Analysis

Design of the TALENs DNA is done by choosing the specific DNA sequence where you
would like to induce a double-stranded break, then customizing the TALEN s binding domain to
target the chosen DNA sequence.
All components necessary for making TALENs are supplied in the Golden Gate TAL
Effector TALENS Kit 2.0, which contains a library of plasmids. Each of these plasmids
containing an RVD sandwiched between two type liS restriction enzyme recognition sites.
Type liS restriction enzymes cut DNA at short distances from the recognition site,
creating a break with a sticky end- single strand overhang as shown in Figure 9.

Cutting site

~::~I~~~~t:::::
Recognition site

Cutting site
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Figure 9: Type liS Restriction Enzymes ("Illustrations").

These sticky ends allow the subunits to be assembled in the correct order: the overhang
for subunit 1 of the protein will only link together with the overhang of subunit 2. Therefore,

when all the subunits are digested together with a type liS restriction enzyme and allowed to
undergo a digestion and ligation reaction, all the different subunits are ligated together in the
desired order. This allows for the design of a TALENs protein that will target the sequence of the
user's choosing.

After all of the different RVDs are linked up in the digestion and ligation reaction , the
TALENs DNA plasmid has been created. This DNA is then transformed into E. coli.
Transformation is a molecular biology technique that allows for the insertion of foreign plasmids
into the bacteria. The bacteria then amplify the plasmid to create large quantities of it.
Colony PCR allows for the analysis of DNA sequences, and allows us to detennine the
success of our TALENs creation. In the colony PCR reaction the DNA is amplified and can then
be analyzed by gel electrophoresis and DNA sequencing. Gel electrophoresis is a technique that
allows for the determination of the size of a segment of DNA, and DNA sequencing allows for
the determination of the exact base pair sequence of a segment of DNA.

Results

It was expected that our gel electrophoresis results would show a band which was

approximately 1200 base pairs in length because our group knew the size of all the individual
components which made up the TALENs DNA. Our group was able to obtain our expected
results, as seen in Figure 10.

Figure 10. Gel Electrophoresis results of TALENs DNA.
After detetmining that our TALENs DNA was the right size, our next step was to
determine the RVDs had linked in the con·ect order. This was done by sending the TALENs
DNA out for sequencing. Because our group knew the DNA sequence of each of the individual
RVDs, we were able to determine what the DNA sequence of the TALENs DNA obtained from
colony PCR should be. We compared the expected DNA sequence and the DNA sequence
obtained from the sequencing company and found that our results matched the expected DNA
sequence. This indicated we had been successful in creating TALENs DNA whose RVD
components were linked up in the order we desired.
Our group has successfully created the TALENs DNA and is currently finishing the final
steps of preparing the TALENs DNA for microinjection. When creating the plasmids that
contain the TALENs DNA, only 10 subunits can be linked together in one reaction. The DNA
we are ereating contains 19 subunits. Therefore, creating the full length TALENs DNA plasmid

is a two step process. The first step involves combining subunits 1-10 in one reaction and
subunits 11-19 in another. This creates the two halves of the TALENs DNA. The second step
combines these two halves together, creating a DNA plasmid containing the full length T ALENs
DNA. Our group was able to successfully create the four halves ofTALENs DNA necessary for
our project.

Back-up Plan
Our group's back-up plan was to repeat the experiment, troubleshooting various
components of the reactions, until we were able to successfully create the TALENs DNA. This
would allow us to optimize the process of creating the TALENs DNA until we could
successfully create it. Additionally, we have maintained a detailed notebook for future student
researchers to follow, which allows for the continuation of the project.

1.3 Microinjection
Introduction
Once we have successfully transcribed our TALENs DNA into mRNA with the in vitro
transcription kit, we will be microinjecting the mRNA along with our repair plasmid into the
gonad of the C. e!egans. Microinjection is defined as ''the use of a glass micropipette to inject a
liquid substance at a microscopic or borderline macroscopic level" (Evans). This can be seen in
Figure II.

Figure II: Microinjection into C. elegans.

Details and Key Constraints
The C. elegans are one millimeter in length and therefore the injection process must be
precise. A high resolution-inve1iing microscope with a microinjecting device to hold the
micropipette in place is used.

Detailed Design Description and Analysis
Once inside the gonad of the C. elegans, the developing oocytes will take up the DNA
and mRNA, and their ribosomes should then translate the TALENs mRNA into TALENs
protein. The TALENs protein can then target and bind to the desired sequence on the lin-31 gene
and create a double stranded break at the potential docking site. The ends of our repair plasmid
should be complementary to the break in the genome and hopefully integrate into the C. elegans
DNA through homologous recombination.
If the repair plasmid is able to successfully integrate into the genome at the created
double stranded break, the C. elegans' progeny should have the mutated version of the lin-31
gene. The docking site on LIN-31 will be altered, making MAP kinase unable to recognize it as a

phosphorylation target. The surrounding cells will then not receive the correct signals and a
vulva will not develop. Because C. elegans are hermaphrodites and contain both sex organs, the
progeny will develop and be unable to escape through the vulva. We will then observe a "bag of
worms," or an adult worm with live progeny inside, this is shown in Figure 12.

Figure 12; Bag of worms phenotype.

Results
Unfmtunately, we were unable to reach this step in our experiment before June.
However, once we are able to successfully create TALENs mRNA from our T ALENs DNA, we
believe this process will be straightforward and easily accomplished. We should be able to obtain
results fairly quickly because of the shmt maturation cycle of the C. elegans.

1.4 Screening for Results
Introduction
If the activity of LIN-31 is disrupted, unspecified cells in C. elegans do not receive the
signal to develop into vulva cells and the organism will display the vulvaless phenotype. This is

a convenient phenotype to use to confirm our success because it is easily visible. As seen in
Figure 13, it is easy to distinguish between vulvaless and wild type C. elegans.

Figure 13: Comparison of C. elegans phenotypes (Rawat).

It is expected that the C. elegans that were not mutated by TALENs will display the

wildtype phenotype, while the mutated C. elegans will display the vulvaless phenotypes. These
phenotypes will be determined by visualizing the organisms under a dissecting microscope.
A successful mutation will then be confirmed by analyzing the DNA of the vulvaless C.
elegans. This will be done by sending out their lin-31 DNA for sequencing. The DNA sequence

of a successful mutation will contain the repair plasmid sequence insetted at the cut site on lin31; this is shown in Figure 14.

~ Mutated Gene
Figure !4: DNA sequence containing the desired mutation of /in-31.

Details and Key Constraints

Each animal is injected and allowed to grow for several days on Nematode Growth
Media plates at 20-25 degrees. After that time the injected C. elegans should have produced
offspring that are now old enough to be screened for phenotypes under a dissecting microscope.
The C. e!egans with the correct phenotype are picked and lysed for their DNA. This DNA is then
amplified with PCR and sent out for sequencing.
Detailed Design Description
By mutating the lin-31 gene in C. elegans we are affecting the vulval cell development in
the organisms. C. e/egans are hermapluodites and therefore able to fertilize internally. When this
occurs in a vulvaless C. e/egan the progeny are unable to escape and therefore begin consuming
the original organism. This results in the phenotype commonly referred to as a bag of worms.
This can be seen above in Figures 12 and 13.
Detailed Supporting Analysis

C. e/egans have been studied extensively and shown to have many different mutant
phenotypes. Due to their self-fertilization capabilities they allow us to study cell fate
determination by their ability or inability to develop vulvas and the visible phenotype occurs as a

result. The vulvaless phenotype has been induced through other methods of mutating the genome
of C. elegans such as exposure to radiation.

Expected Results
For our results we would expect to see C. elegans with the vulvaless phenotype. When
the DNA from these C. eiegans are sent out for sequencing we would expect them to contain the

lin-31 sequence shown in Figure 14 that codes for the alanine amino acids in the place of the
arginine and lysine residues in the potential docking site.

Back-up Plan
If the progeny do not display the expected phenotype, we will run a Cel-l assay. The Cell assay allows us to screen many C. elegans, with any mutation, at one time. Cel-l is an enzyme
isolated from celery that cuts mismatched DNA. We would expect that the pools of C. elegans
that contain individual C. elegans with mutations would show mismatches when lysed and the

lin-31 gene is amplified through PCR. The PCR product fi-om the pools of worms is then
incubated with Cel-l, run on an agarose gel, and the fragment is cut. We would see three bands,
indicating that at least one of the wmms in the original pool contains a mutation. The three bands
are only present when the mutated DNA creates a mismatch with the wild type DNA. From
there, individual worms can be mixed with wild type worms, lysed, amplified with PCR, and
incubated with Cel-l to dete1mine which individual worms contain mutations. Then, these
mutant PCR products can be sent for sequencing.

Materials and Methods

For this step we will require a dissecting microscope and the microinjected C. e/egans
and their progeny. In order to isolate the DNA for sequencing from the C. e/egans the worms are
placed in a buffer containing Proteinase K, and heated in the thermocycler. This lyses the worms,
releasing their DNA, which is then used in a PCR reaction to amplify the docking-site coding
fragment of the /in-31 gene.

Results
Until the repair plasmid and TALENs are injected we cannot complete this step. However
this step is straightforward and will take little time to complete.
Discussion

If this step is successful it will not only confirm that TALENs is an effective technology
for genome editing, but also support the research done to prove that the sequence targeted in this
experiment codes for a docking site on LIN-31. This has the potential to contribute to the
research on TALENs as well as research on LIN-31 and the Ras/MAP kinase pathway.

Summary and Conclusion
TALENs, transcription activator-like effector nucleases, are a genetic engineering
technology that can be used for targeted gene modification. For our senior design project we
used TALENs to explore their potential for use in gene therapy. Gene therapy is an exciting field
as it provides the potential to cure many genetic diseases. Gene therapy offers the potential for a
cure to these diseases because it can be used to permanently repair the genome. Specifically, our
project with TALENs will provide a service to society as it will give rise to a better
understanding of the technology and its uses as a genetic engineering research tool.

Over the course of our senior year, we have been able to successfully construct T ALENs
DNA that codes for a protein that will bind specifically and cut the genome at our desired
location. We have validated the ability to create customizable DNA binding domains designed
by the user. The materials and methods involved in creating TALEN s are fairly common and
straightforward. A majority of laboratories have all of the necessary facilities and knowledge to
utilize this technology. Such accessibility is testament to the relevance and future of the TALENs
technology. We have high hopes that our work will lead to further exploration ofTALENs at
Santa Clara University and that researchers will continue to improve TALENs for its use in gene
therapy.

Engineering Standards and Realistic Constraints
Health & Safety
Current Concerns
When evaluating the health and safety concems associated with the TALENs technology
it is important to consider them in the context of our project as it stands currently and in the
context of future applications in gene therapy. Currently our own safety is the greatest concern.
While working with any toxic chemicals or dangerous microorganisms it is impmtant that we are
always using good lab technique to protect ourselves and those in the lab around us. Hazards in
our lab include ethidium bromide (a known carcinogen), E. coli bacteria, flammable chemicals,
and UV light. It is impmtant that we always use the appropriate precautions such as wearing
gloves and disposing of all materials properly.

Future Concerns
When considering the safety and risk involved with future treatments for patients using
TALENs there are many. It is important that we cunently document all observations so that
when the treatment is being tested in humans, we can provide them with as much information as
possible. Informed consent requires that the patients and doctors know the risks involved with
the treatment. In order to fully explain the risks, there has to be good documentation tlu-oughout
the entire development, especially in regards to any adverse or unintended effects. While all
clinical trials involve risk, it is important that all possible precautions are taken to minimize these
risks before they are tested in humans.
The need for precautions in using genetic engineering teclmologies is highlighted by a
recent publication about targeted genome editing; specifically, CRISPR (a genetic engineering
technology similar to TALENs) was used to edit the genome of non-viable human embryos
(Liang). This research team attempted to edit the gene that causes P-thalassacmia, a genetic
mutati on invo lved in blood disorders (Cyranoski). Eight-six embryos were used in this
experiment, and only four contained the correct mutation (Cyranoski).
Purther data analysis indicated that many of the embryos used in the study contained offtarget mutations, meaning that CRISPR had moclitiecl the embryo's genome in an undesired
location. T his is a major health and safety threat because these mutations could be harmful. This
study hi ghlights the health and safety concerns surrounding these genetic engineering
teclm ologies because they do have the potential to mutate the genome in undesired locations.
Therefore. further research needs to be done to ensure that these technologies only mutate the

genome at a specific, targeted location, minimizing the health and safety risks associated with the
technology.

Social Considerations
Introduction
The ability to specifically target a desired location of the genome is an incredibly
powerful tool with the potential to be developed for numerous applications. The application of
gene therapy is an honorable one that aims to provide relief to victims of genetic disorders.
Proponents argue that if we have the ability to prevent excruciating pain then we should be
obligated to do so, while opponents believe gene therapy is a slippery slope to genetic
enhancement. Whatever the case, many other considerations need to be taken into account that
will ultimately affect social perceptions of gene therapy. For example, if gene therapy becomes a
viable option in the future, should women be required to receive genetic screening? Is it wrong
for a family to bring a child into the world if they know his or her life will be filled with
suffering? This brings up the question of when exactly such testing should be performed. Also, if
people or companies have the ability to alter a genome, are they creating new patentable life
forms? The Supreme Court decision, Diamond vs. Chakrabarty, granted permission for just that
(Ramsdale). To many it seems wrong that anyone can owu the rights to life.
Future Directions
Society ultimately needs to decide whether or not to pursue technology used for gene
therapy and how it will be done. Many members of the scientific community believe the FDA
and RAC are too restricting and discourage progress and advancements. Others are fearful that
we are pursuing dangerous technologies too hastily. The public will need to decide for itself and

make crucial decisions with little guidance or technical understanding. It is therefore impm1ant
that we remain cautiously optimistic of technology that has the potential to revolutionize science
and the way we approach treating genetic diseases. With so many variable outcomes, it is not
unwise to consider what exactly such a powerful tool can bring about.
Sustainability

Introduction
The science of sustainability involves " examining the interactions between human,
environmental, and engineered systems to understand and contribute to solutions for complex
challenges that threaten the future of humanity" (Clark). Our project aimed to impact this field
by exploring a technology that has the potential to provide permanent solutions to debilitating
genetic disorders. Because the T A LENs teclmology has a DNA binding domain attached to a
DNA cleavage domain, the user is able to create a protein that can specifically target and create a
double stranded break at any desired location. The ability to target an exact location allows for
efficient and repeatable results.

Sustainability and TALENs
Since the TALEs used in the TALENs technology are designed after those found in the
bacteria Xanthomonas, the TALENs teclmology is an efficient and accurate resource. The
TALEs recognize DNA sequences based on RVDs, or two amino acids found within the longer
repeat sequence from which they are coded. The genetic constructs that encode for the TALEs
are produced by gene synthesis or modular assembly. These techniques are considered
economical and are offered by many companies worldwide. It is therefore relatively easy to both
create and obtain a library ofTALEs. The organization Add gene, provides a plasmid kit

containing a library ofTALEs for the creation of customizable TALENs proteins. If the
technology were to be fmther developed and validated, the creation of personalized TALENs
would be a sustainable and desirable option.

Manufacturability
Our project involved exploring the potential ofTALENs for as a research tool. In order to
ensure the integrity of our research and design project, the whole group was trained in good
laboratory practices. This included keeping a detailed lab notebook and recording all data and
results. Each member of the group analyzed data separately and then compared our findings.
This helped ensure our data's accuracy, allowing us to ensure the integrity of our research.
Keeping a detailed lab notebook will make the transition to manufacturing TALENs
easier. If our project proves successful, eventually many different TALENs could be
manufactured for gene therapy. This process will require a scale-up of our reactions to industrial
levels. However, we have figured out the necessary concentrations for all our reactions, making
this scale-up process easier and more feasible.

Ethical Considerations
Introduction
The presidential commission for the study of bioethical issues developed a framework
for addressing developing technologies such as gene therapy. Their main focus is on defining
and applying the concept of responsible stewardship. Responsible stewardship is the
responsibility of us all to act in a way that demonstrates concern for those that cannot represent
themselves, such as children, the environment, or the future. This means ensuring we are fully

aware of the risks and consequences of our actions on others. The commission's attitude towards
addressing new technologies coincides with the Markkula Center for Applied Ethics' Framework
for Thinking Ethically.
The Center's approach begins with recognizing an ethical issue. The technology of gene
therapy is a rapidly growing field that has the potential to prevent, treat, or cure genetic diseases.
While this capability would allow for the treatment of horrible diseases such as cystic fibrosis or
sickle cell anemia, if analyzed ethically, it may seem too good to be true. Gene therapy could
provide a solution for those suffering from debilitating illnesses, but it could also allow people to
alter undesirable traits or create designer babies.
This idea raises many ethical questions. Should people be able to use genetic engineering
to fix any trait or characteristic they are unsatisfied with? Where is the line drawn between
someone that wants to use gene therapy to treat muscular cell dystrophy and someone that
wishes they were genetically more capable of building muscle? The amazing capability of gene
therapy to do good could quickly create unforeseen consequences and change the world in which
we live. Parents would have the ability to alter their children, threatening their autonomy.
According to Kantian ethics, because humans are autonomous agents and capable of making
rational decisions, we all deserve dignity and respect. Autonomy gives everyone the right to
make fully informed decisions about what happens to them and whether or not they want to
participate in medical research. Altering a child's genetic information strips them of this choice.
It is imp01tant that we recognize this and consider all possible outcomes and ethical responses.

Although the gene therapy technology is nowhere near this advanced, by looking ahead we will
be prepared if human experimentation becomes a possibility.

Another question raised by the TALENs technology is: whether or not the ability to alter
an organism's genome is playing God. If the technology continues to develop, it is likely to be
used to treat human diseases. One argument states that human DNA should be off-limits to any
tampering. We should not interfere with natmal selection or challenge our relationship with
nature. If we allow pride or arrogance to cloud our judgment, we will lose reverence for life. An
opposing argument believes that if we have the capability to cure honible diseases and ease
potentially excruciating pain we have the responsibility to do so. The solution is in finding a
balance between these two viewpoints. Using genetic engineering to alter a person's basic traits
would be an abuse of the technology. The technology should be respected and used only to
provide relief to those suffering from terrible illnesses. Acknowledging the sacredness and
privilege of life will ensure that such a powerful tool will not be abused.

Evaluation ofAlternative Actions
However, before we can realistically predict the development of gene therapy
technologies, we need to ensure we have a deep understanding of the technology and its
potential. Judgment cannot be made upon something that is not fully understood. Before
committing to using TALENs as the chosen fmm of genetic engineering, a full analysis of
competing technologies should be done in order to either discover a more ethical method or
confirm that TALENs is the best option. Some of the competing technologies include
retroviruses, zinc finger nucleases, and clustered regularly interspaced short palindromic repeats
(CRISPR). TALENs outcompetes each of these technologies because it has less off target effects
and is therefore the safest option. Off target effects refers to the genetic engineering tool (such as
CRISPR) integrating at the wrong place in the genome. The consequences of this could be
catastrophic because the technology could alter the genome in an uncontrolled manner, causing

unknown effects on the genome. This occurred in a clinical trial that aimed to use retroviruses to
treat severe combined immunodeficiency. In this trial, eleven children were given retroviral
treatment, and nine recovered. However, of these nine children, four developed leukemia. It was
discovered that the retroviruses had randomly integrated in the genome and turned on an
oncogene, giving the kids cancer (Check). This highlights the need for the development of new
approaches to gene therapy, specifically approaches which are safe and effective.
From a utilitarian standpoint, TALENs would be the obvious choice since it can
accomplish what the other technologies do more effectively and in a less harmful manner. It
provides the most hope for futthering the field of genetic engineering because it is targeted,
efficient, and safe.

Choice of C. elegans
Our project aimed to demonstrate the safety and efficacy ofTALENs by using the
technology in a model organism, nematode C. elegans. This allowed for the study of the safety
ofTALENs without experimentation in humans. Additionally, it will give the scientific
community a better understanding of the technology, which will aid in determining regulation as
to what TALENs can and cannot be used for.
Even though the use of a model organism prevents experimentation in humans, there are
ethical concerns that must be taken into consideration when conducting research on living
organisms. C. elegans are considered a model organism in the scientific community because they
are one of the simplest systems to possess a nervous system, they can be frozen and thawed
without damaging the organism, and they possess a quick reproduction rate (Comstock) .
Therefore these nematodes are well studied and have been used in a variety of scientific

experiments. However, there are some questions which must be addressed when conducting
research on live organisms. These include: Will the experiment create an unnatural organism?,
Who takes responsibility for the organisms used?, and How will the organisms be treated during
the experimentation?. Our group carefully considered the implications of each of these questions
before moving forward with our project.
We detennined that yes, if successful, our project will create an urmatural organism. We
used TALENs to mutate the lin-31 gene of C. elegans in order to learn more about cell fate
specification in a RAS/MAPK signaling pathway. Therefore our project aimed to create C.
elegans with a mutated signaling pathway. We detennined that the benefits gained from learning

more about this signaling pathway and demonstrating the safety and efficacy ofTALENs
outweighed the negative consequences of creating a mutated organism.
Our group also addressed concerns of who would take responsibility for the organisms
used in our experiment and how they would be treated. C. elegans are organisms that respond to
stimuli and thus could be subject to inhumane laboratory practices. We addressed these concems
by choosing an advisor who is well experienced in working with C. elegans. Our advisor has
many years of experience in working with C. elegans and therefore was able to train us in proper
handling of the organisms. Our group was trained to use C. elegans in a manner that minimizes
the pain the organisms could experience and ensured that the organisms are not subjected to
inhumane laboratory practices. Both our senior design group and our advisor ultimately took
responsibility for the organisms used in the experiment and therefore committed ourselves to
conducting our experiment in accordance to good lab techniques.

C. elegans do have a nervous system and therefore could respond to pain caused by
improper handling. However their nervous system is not highly developed and the level of pain
would be minimal. Additionally, our project itself does not cause pain to the C. elegans as the
TALENs mRNA is microinjected into the organisms and then the C. elegans ribosomes are used
to produce the TALENs protein in vivo. Microinjection is a process that uses a very thin needle
to inject mRNA into the C.elegans, the needle is so thin that it can barely be felt by the
organisms. After microinjection, our experiment simply involved microscopically monitoring the
development of the C. e/egans. This meant the C. elegans would experience minimal handling
by our group. This allowed our group to ensure that the organisms were humanely treated and
allowed our group to take responsibility for the organisms that we genetically altered.

Future Implications
Once the technology has been thoroughly assessed and all potential outcomes considered,
a choice needs to be made about whether or not to continue developing the technology. The
presidential commission for the study of bioethical issues created a method for approaching this
decision making process called prudent vigilance. Prudent vigilance is the need to continue
assessing the benefits and risks of a technology, both before, during, and after its development.
As TALEN s is explored and implemented, experimental results will provide fmiher information
about the efficacy and safety of the technology. Based off of this data, we can reevaluate the
direction and goals of the technology and our project. In this matmer, scientific advancement will
not be hindered but it will also not progress unchecked. Continuing to evaluate the ethical issues
of a project as it develops ensures it will not take an undesirable direction and that the
community stays informed and involved.

Team and Organizational Ethics
We upheld distributive justice by equally distributing the work between the members.
One way we ensured that the work was distributed evenly was by everyone scheduling the same
number of hours in the lab. We also tried to ensure that there were at least a few hours in which
we were all present in the lab together, so that everyone could have a voice in the decisions. In
this way we used technology to assist us in communication between our members. We each
prepared our own lab notebooks as well as created a Google doc with the main experiments for
the day so that each member knew what had been done, and what still needed to be done. For
resolving any issues and working to uphold the common good of the group we established that if
any conflict between members arose we would have a conversation and resolve the issue
ourselves. If it could not be resolved between two members we would bring the other member of
the group in to help address the problem. As a last resott we would speak with the advisor if an
agreement could not be made between group members.
In our project it was important that we analyzed the contributions that everyone made to
the project, including our advisor and lab technician. Our team had the privilege of working with
Dr. Miller, our advisor, and her employees to contribute to their research. When preparing our
report we ensured that we gave credit to the other members of the lab for their contributions to
the project, taking into account the justice and fairness of our project. All the reports were
written and prepared by our team members. In addition we wanted to give credit to the previous
researchers who provided the framework for us to do our work. Many of these researchers are
included in our works cited, however two groups were especially impottant in our research. The
first group was Carson Harms and Serena Lertkantitham who worked with TALENs in the Miller

lab the previous year and laid the framework for our project. The second group was the Voytas
lab group. The Voytas lab pioneered the TALENs technology and produced the kit we used.
As demonstrated by our continuation of the project fi·om the previous year it was
important that we maintained detailed documentation of our work. One of the virtues possessed
by good scientists and engineers is the ability and dedication to habitually document their work.
Our team aimed to be thorough in describing our work, so that future scientists and engineers
could use our work. In our project the goal was to prove the efficacy and safety of TALENs, and
this could only be achieved with thorough, detailed reports. In addition all results and data were
accurate and true. No data was falsified or exaggerated to support our hypothesis.
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Appendix
Table 2. Modified Gannt Chart.
Task description

Complete Lab Safety
School of Engineering Grant
Proposal
Identify target Sequence and
RVD
Make Repair plasmid
Golden Gate reaction 1-1
Golden Gate reaction 1-2
Golden Gate reaction 2-1
Golden Gate reaction 2-2
Check 1-1 by colony PCR
Check 1-2 by colony PCR
Check 2-1 by colony PCR
Check 2-2 by colony PCR
Check 1-1 by sequencing
Check 1-2 by sequencing
Check 2-1 by sequencing
Check 2-2 by sequencing
2nd Golden Gate for plasmid 1

Start date

Finish date

Progress

9/30/14
10/2/14

10/2/14
10/10/14

completed
completed

10/20/14

10/20/14

completed

TAL targeter

10/27/14
10/27/14
10/27/14
10/27/14
10/27/14
10/31/14
10/31/14
10/31/14
10/31/14
1/26/14

10/31/14
11/18/14

completed
completed
completed

11/7/14
1/23/14

completed
completed

11/7/14

completed

1/15/15

completed

pLM 545
RVD colonies
RVD colonies
RVD colonies
RVD colonies
Taq supplies
Taq supplies
Taq supplies
Taq supplies
primers
primers
primers
primers
golden gate primers
and colonies
golden gate primers
and colonies

1/26/14
1/14/15

2nd Golden Gate for plasmid 2
Check plasmid 1
Check plasmid 2
Make TALENs mRNA for 1
Make T ALENs mRNA for 2
Inject mRNA
Pick correct phenotypes
Preform Cel-1 assay
Sequence correct C. elegans
Write Thesis lntro
Write Thesis Body
Complete Thesis
First Draft of Presentation
Final Presentation Complete

Resources

completed
completed
completed
completed
completed

